Skip to main content

Table 3 Relationships between serum CA 19-9 and clinicopathological factors in clinical stage I lung adenocarcinoma patients

From: The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma

Patient characteristics CA 19-9 positive n (%) (n = 54) CA 19-9 negative n (%) (n = 62) P
Age (years)
 SD 9.1 8.3 0.028
 Mean 69.2 65.6
Sex
 Male 29 (54) 30 (48) 0.582
 Female 25 (46) 32 (52)
Smoking status
 Never 30 (56) 32 (52) 0.712
 Current or former 24 (44) 30 (48)
Vessel invasion
 Absent 39 (72) 55 (89) 0.032
 Present 15 (28) 7 (11)
Pleural invasion
 Absent 41 (76) 57 (92) 0.023
 Present 13 (24) 5 (8)
p-N status
 No metastasis 47 (87) 59 (95) 0.184
 Metastasis 7 (13) 3 (5)
Cancer invasive factor
 Negative 29 (54) 49 (79) 0.005
 Positive 25 (46) 13 (21)
c-Stagea
 IA 44 (81) 50 (81) 1.000
 IB 10 (19) 12 (19)
p-Stageb
 I 45 (83) 59 (95) 0.063
 II/III 9 (17) 3 (5)
PAS stain
 Negative 32 (59) 54 (87) 0.001
 Positive 22 (41) 8 (13)
  1. CA 19-9 carbohydrate antigen 19-9, PAS periodic acid-Schiff stain, SD standard deviation
  2. a Clinical stage; b Pathological stage